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exposed areas, with ﬂat-topped scaly lesions on the dorsum of both
hands and wrists thought likely to be Gottron's papules. Serum crea-
tine kinase (CK) was elevated at 3012 IU/L (n = 30–135).
Medical history includedhypothyroidism, hypertension, osteoporosis,
depression and previous lumbar discectomy for degenerative disease.
She was prescribed levothyroxine, ﬂuoxetine, amitriptyline, calcium
carbonate, alendronic acid, lisinopril, paracetamol and omeprazole.
There was a history of ovarian cancer in the patient's mother.
Dermatomyositis was suspected and a skin biopsy was performedIntroduction
Dermatomyositis is a rare, idiopathic, inﬂammatory myopathy with
reported incidences varying from 0.5–0.89 per 100,000 (Robinson and
Reed, 2011). There is a well documented relationship with malignan-
cies such as breast, lung or ovarian cancer (Sigurgeirsson et al., 1992;
Hill et al., 2001) and it has previously been reported as a presenting fea-
ture of ovarian cancer. However, previous reports in ovarian cancer are
of cases treated with primary de-bulking surgery. We believe this to be
the ﬁrst report of a case treated with neo-adjuvant chemotherapy and
interval debulking surgery.
Case
A 57 year old Caucasian lady presented to her General Practitioner
with a pruritic rash on her anterior chest, upper arms, hands and face.
Two weeks later proximal myalgia and stiffness of all four limbs de-
veloped and a dermatology opinion was sought. On physical exami-
nation there was an erythematous maculopapular rash affecting theestern General Hospital, Crewe
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terface dermatitis consistent with a collagen vascular disease or der-
matomyositis [Fig. 1].
One week later the patient was admitted to hospital with progres-
sive proximal muscle weakness. CK had risen to 11,608 and erythrocyte
sedimentation rate was elevated at 46. Temperature was elevated at
38.2 °C. Physical examination revealed a rash affecting her chest, back
and upper arms (shawl distribution), muscle weakness predominantly
affecting hip ﬂexion and shoulder abduction, and a palpable mass in
the right iliac fossa.
Prednisolone 40 mg was commenced with a dose increase to
60 mg after 10 days due to lack of response. CK fell to 2279 but with-
out any symptomatic improvement and she remained bedbound in
hospital.
CT scan of chest, abdomen and pelvis revealed a 9.5 cm × 8.8 cm
lobulated, cystic adnexal mass with multiple peritoneal deposits.
Biopsy of the pelvic mass was consistent with a high grade serous
carcinoma of ovarian or primary peritoneal origin.
Neo-adjuvant chemotherapy with Carboplatin AUC-6 and Paclitaxel
175 mg/m2 was commenced as an in-patient 1 month after presenta-
tion. Ca125 fell from 2231 KU/L to 172 after 3 cycles of chemotherapy,
all given as an in-patient. CK rose to 3256 during week 1 of chemother-
apy but waswithin normal range at 51 by cycle 3. Muscle weakness im-
proved during chemotherapy and shewasmobilising independently on
the ward after 2 cycles. A relapse of her photosensitive rash responded
to hydroxychloroquine. Prednisolone was gradually reduced to a dose
of 30 mg.
CT scan after 3 cycles showed a good partial response to treatment
and a fourth cycle of neo-adjuvant chemotherapy was given as an
out-patient.
Sheproceeded to a laparotomy, anterior resection of the rectumwith
re-anastomosis, bilateral salpingo-oophorectomy, hysterectomy and
omentectomy without intra-operative complications. Post-operatively,.
Fig. 1. Images of the skin biopsy showing the vacuolar interface dermatitis at 10× (a)
and 40× (b).
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subsequentmild proximalmuscleweakness, responded after increasing
prednisolone to 40 mg.
Following cytoreductive surgery, a 1 cm peritoneal deposit remained
in an inaccessible area beneath the right hemi-diaphragm. Her post-
surgery CT scan 6 weeks later identiﬁed diffuse low volume peritoneal
disease in the right and left paracolic gutters. Two further cycles of
post-operative carboplatin and paclitaxel were given, with a further re-
sponse but persistent low volume peritoneal disease on her end of treat-
ment CT, and Ca125 of 54. No dose reductions or delays were required
during chemotherapy and the only grade 2 toxicity experienced was alo-
pecia. Prednisolone was gradually reduced to a maintenance dose of
10 mg.
The patient experienced exacerbation of her skin rash 3 months
after completion of chemotherapy, but remained asymptomatic of her
ovarian cancer. There was a rise in Ca125 and CK, and restaging CT
scan revealed new low volume ascites and an increased volume of peri-
toneal disease. There was a subsequent relapse of proximal muscle
weakness. Prednisolone was increased to 40 mg, with an improvement
of the skin rash and fall in CK, although muscle weakness persisted.
Chemotherapy for relapsed disease with weekly carboplatin and
paclitaxel and 3-weekly bevacizumab was commenced 5 months
after completion of her post-operative chemotherapy. Bevacizumab
was stopped after the ﬁrst cycle due to haematuria. Ca125 levels
were rising after 4 months of second-line chemotherapy, withdisease progression conﬁrmed on CT. Although CK levels continued
to fall, disease progression coincided with worsening proximal mus-
cle weakness and new difﬁculties swallowing.
Chemotherapy was stopped and the patient died from progressive
disease 18 months after initial presentation.
Discussion
The association between dermatomyositis and malignancy is now
well recognised. In one Swedish series, 15% of patients presenting
with dermatomyositis were subsequently found to have a malignancy
(Sigurgeirsson et al., 1992)while a later pooled analysis of Scandinavian
studies identiﬁed amalignancy in 32% of patientswith dermatomyositis
(Hill et al., 2001). The increased risk of ovarian cancer is also recognised
with a reported incidence in dermatomyositis of 13.3% (Cherin et al.,
1993), and a reported standardised incidence ratio of 10.1 (Hill et al.,
2001). Ovarian cancer is commonly advanced at the time of diagnosis;
in one case series of 14 patients, all had stage III or IV disease at presen-
tation (Davis and Ahmed, 1997).
Clinical features of dermatomyositis include photosensitivity affect-
ing the upper back, chest, and shoulders (shawl sign), face, ears and
hands. Further cutaneous features includeGottron's papules, a heliotrope
rash and periungual telangiectasia. Muscle weakness predominantly
affects proximal muscles and is symmetrical. Skin and muscle disease
may occur concurrently or independent of each other. Other features in-
clude dyspnoea due to weakness of the intercostal muscles or interstitial
lung disease; myocarditis leading to heart failure or arrhythmias; and
dysphagia due to oesophageal involvement. CK levels are commonly
elevated and used tomonitor disease activity, but can be normal in active
disease. (Callen, 2000; Stone, 2010; Smith et al., 2009).
The pathogenesis is that of a microangiopathy, characterised by
complement deposition in the microvasculature of the muscle and
antibody mediated capillary destruction. Conﬁrmation of the diagno-
sis requires tissue biopsy of the skin or muscle. Skin biopsy reveals an
‘interface dermatitis’ on immunoﬂuorescence, with vacuolar changes
at the dermal-epidermal junction and a perivascular lymphocytic in-
ﬂammatory inﬁltrate (Stone, 2010; Smith et al., 2009). Muscle biopsy
demonstrates a perivascular inﬂammatory inﬁltrate, capillary obliter-
ation, capillary thrombosis, endothelial cell damage and perifasicular
atrophy (Robinson and Reed, 2011; Stone, 2010).
Treatment with high dose glucocorticoids, such as prednisolone 0.5–
1 mg/kg, may result in an improvement of CK levels within the ﬁrst cou-
ple ofweeks. There is often adelay beforemuscle strength returns.Muscle
weakness may respond better than skin rash. However, steroid induced
proximal myopathy is common and can present similarly to active
disease. Second line treatment with azathioprine, methotrexate or
cyclophosphamide may be required for aggressive disease. Hydroxy-
chloroquine may be useful as a steroid sparing agent (Robinson and
Reed, 2011; Callen, 2000; Vermaak and McHugh, 2012).
Independent of an underlying malignancy dermatomyositis may
have a poor prognosis with reported rates of remission range from
25%–77%. Recent series report a 5 year OS of 75–90%. Underlying
malignancy is an established risk factor for poor prognosis in
dermatomyositis, with lung, cardiac and oesophageal involvement
also poor prognostic factors (Robinson and Reed, 2011; Marie, 2012).
There is little evidence to guide treatment of dermatomyositis in
the presence of ovarian cancer, although historically this has involved
surgical debulking with or without post-operative chemotherapy.
Prognosis is poor with mortality reported at 100% for patients with
ovarian cancer and dermatomyositis in one series (Davis and
Ahmed, 1997). Our case demonstrates that dermatomyositis in this
setting can improve with neo-adjuvant chemotherapy and interval
debulking surgery, in conjunction with corticosteroid therapy and
physiotherapy. Skin rash may persist despite improvement in muscle
function and treatment of the underlying ovarian cancer. Worsening
of the skin rash may also be the ﬁrst sign of relapsing disease.
15A. Christie et al. / Gynecologic Oncology Reports 6 (2013) 13–15Recognition of the high risk of ovarian cancer in the dermatomyositis
population, particularly in females aged over 40, can expedite
diagnosis.
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